Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
Holding PCRX?
Track your performance easily
PCRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.16 - $35.95
Previous Close$13.49
Volume984.13K
Average Volume (3M)1.42M
Market Cap
$622.25M
Enterprise Value$866.62M
Total Cash (Recent Filing)$404.23M
Total Debt (Recent Filing)$648.60M
Price to Earnings (P/E)10.5
Beta0.92
Next Earnings
Oct 31, 2024EPS Estimate
$0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.29
Shares Outstanding46,126,946
10 Day Avg. Volume1,095,571
30 Day Avg. Volume1,416,224
Standard Deviation0.11
R-Squared0.15
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.71
Price to Sales (P/S)0.88
Price to Cash Flow (P/CF)2.80
P/FCF Ratio2.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.26
Enterprise Value/Gross Profit1.77
Enterprise Value/Ebitda6.16
Forecast
1Y Price Target
$19.88Price Target Upside38.58% Upside
Rating ConsensusHold
Number of Analyst Covering9
Pacira Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Growth ExpectationsPCRX expects substantial growth for Exparel from 2025 with the implementation of the NOPAIN Act.
Market OverreactionAnalyst believes the market is overreacting to the court ruling and sees the stock weakness as wildly overdone.
Patent LitigationPacira has four additional OB-listed patents in earlier-stage litigation against eVenus, and the recent ruling does not invalidate those.
Bears Say
Financial PerformanceWith now a path for generics to enter the market, a substantial decline in Pacira’s top and bottomline is expected, and no clear path for recovery is seen.
Market CompetitionExparel composes ~80% of PCRX’s revenue, the vast majority of which will likely get eroded if PCRX can’t successfully defend other patents.
Patent IssuesThe U.S. District Court for the District of New Jersey ruled that patent #11,033,495 ('495) on Exparel is invalid.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PCRX FAQ
What was Pacira Pharmaceuticals’s price range in the past 12 months?
Pacira Pharmaceuticals lowest stock price was $11.16 and its highest was $35.95 in the past 12 months.
What is Pacira Pharmaceuticals’s market cap?
Currently, no data Available
When is Pacira Pharmaceuticals’s upcoming earnings report date?
Pacira Pharmaceuticals’s upcoming earnings report date is Oct 31, 2024 which is in 43 days.
How were Pacira Pharmaceuticals’s earnings last quarter?
Pacira Pharmaceuticals released its earnings results on Jul 30, 2024. The company reported $0.89 earnings per share for the quarter, beating the consensus estimate of $0.699 by $0.191.
Is Pacira Pharmaceuticals overvalued?
According to Wall Street analysts Pacira Pharmaceuticals’s price is currently Undervalued.
Does Pacira Pharmaceuticals pay dividends?
Pacira Pharmaceuticals does not currently pay dividends.
What is Pacira Pharmaceuticals’s EPS estimate?
Pacira Pharmaceuticals’s EPS estimate is $0.73.
How many shares outstanding does Pacira Pharmaceuticals have?
Pacira Pharmaceuticals has 46,126,945 shares outstanding.
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Pacira Pharmaceuticals reported an EPS of $0.89 in its last earnings report, beating expectations of $0.699. Following the earnings report the stock price went up 5.681%.
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
Among the largest hedge funds holding Pacira Pharmaceuticals’s share is Ardsley Advisory Partners. It holds Pacira Pharmaceuticals’s shares valued at 17M.
---
Pacira Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$19.88 (38.58% Upside)
$19.88 (38.58% Upside)
Blogger Sentiment
Bullish
PCRX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 41.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $215.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.89%
12-Months-Change
Fundamentals
Return on Equity
7.54%
Trailing 12-Months
Asset Growth
6.77%
Trailing 12-Months
Company Description
Pacira Pharmaceuticals
Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.
---
PCRX Company Deck
---
PCRX Earnings Call
Q2 2024
0:00 / 0:00
---
PCRX Stock 12 Month Forecast
Average Price Target
$19.88
▲(38.58% Upside)
Technical Analysis
Best Analysts Covering PCRX
1 Year
1 Year Success Rate
13/40 ratings generated profit
1 Year Average Return
-10.85%
reiterated a buy rating last month
Copying Oren Livnat's trades and holding each position for 1 Year would result in 32.50% of your transactions generating a profit, with an average return of -10.85% per trade.
---